Norovirus Vaccine - Vaxart

Drug Profile

Norovirus Vaccine - Vaxart

Alternative Names: VXA-G1-1-NN; VXA-G1.1-NN

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaxart
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Norovirus infections

Most Recent Events

  • 03 Nov 2017 Immunogenicity data from a phase Ib trial in Healthy volunteers released by Vaxart
  • 30 Oct 2017 Vaxart plans a phase II norovirus challenge study in Q2 2018
  • 07 Apr 2017 Vaxart initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT03125473)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top